Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tscan Therapeutics Inc (NQ: TCRX ) 5.820 +0.110 (+1.93%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 348,041 Open 5.740 Bid (Size) 5.420 (1) Ask (Size) 6.390 (1) Prev. Close 5.710 Today's Range 5.475 - 5.930 52wk Range 1.930 - 9.690 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News TScan Therapeutics Announces Updates to its Board of Directors June 14, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire The Analyst Landscape: 7 Takes On TScan Therapeutics June 04, 2024 Via Benzinga Performance YTD +1.93% +1.93% 1 Month -30.55% -30.55% 3 Month -20.71% -20.71% 6 Month -2.68% -2.68% 1 Year +169.44% +169.44% More News Read More TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference May 30, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies May 29, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire Key Takeaways From TScan Therapeutics Analyst Ratings May 13, 2024 Via Benzinga Unveiling 4 Analyst Insights On TScan Therapeutics April 23, 2024 Via Benzinga TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 13, 2024 Via InvestorPlace TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update May 13, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors May 09, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting April 24, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics: Q4 Earnings Insights March 06, 2024 Via Benzinga TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares April 24, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting April 22, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Closing of Upsized Public Offering April 19, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering April 17, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering April 16, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities April 16, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer April 08, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday March 22, 2024 Via Benzinga Topics Stocks Exposures US Equities Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With March 17, 2024 Via InvestorPlace TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 March 06, 2024 Via InvestorPlace TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 06, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference February 28, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR February 26, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
